TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05523024

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotc and Berberine
Description: Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
Study: NCT06369597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic telesurgery
Description: Telesurgery by domestic surgical robot
Study: NCT05974384

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No Music
Description: No listening to music while intervention is carried out

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Listening to music while intervention is carried out
Study: NCT05719857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic vein pressure gradient measurement
Description: HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous liver biopsy
Description: Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparametric Abdominal Magnetic Resonance with Elastography
Description: The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
Study: NCT06369597

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Local laparoscopic surgery
Study: NCT06040424

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ipratropium / Levosalbutamol Fixed Dose Combination
Description: New combination test treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium + Levosalbutamol Free Dose Combination
Description: Free combination control treatment
Study: NCT06507319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct bone anchored pull distal slider
Description: distalization from the palatal side only.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect bone anchored dual force distalizer.
Description: distalization from the palatal and buccal sides.
Study: NCT04993092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle energy technique
Description: Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan mobilization technique
Description: Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
Study: NCT04957693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vegan diet and lifestyle changes
Description: vegan diet and lifestyle changes
Study: NCT04747418

Intervention type: PROCEDURE
Intervention: Diagnostic Hysteroscopy
Description: Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy

Intervention type: PROCEDURE
Intervention: Trans-vaginal ultrasound
Description: Trans vaginal ultrasound performed immediately following the diagnostic hysteroscopy ( as sonohysterography)
Study: NCT05481944

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI in patients
Description: Injected MRI

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: MRI in healthy volunteers
Description: non injected MRI
Study: NCT05934708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric leg extension
Description: Participants will complete a 10 x 10 eccentric leg extension on a Cybex Norm dynamometer. Upon arrival, participants will be asked their perceived readiness to perform on a 11 point numeric rating scale. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump. Half way through each set (i.e., after the 5th repetition) participants will be asked to rank their level of difficulty on a 11 point OMNI Res scale. This will occur during each set. Participants will have follow up blood draws, measures of muscle function (i.e, jump height) and soreness measured immediately after and 24 and 48 hours post-exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric leg extension
Description: Participants will complete a 10 x 10 eccentric leg extension on a Cybex Norm dynamometer. Upon arrival, participants will be asked their perceived readiness to perform on a 11 point numeric rating scale. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump. Half way through each set (i.e., after the 5th repetition) participants will be asked to rank their level of difficulty on a 11 point OMNI Res scale. This will occur during each set. Participants will have follow up blood draws, measures of muscle function (i.e, jump height) and soreness measured immediately after and 24 and 48 hours post-exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric leg extension
Description: Participants will complete a 10 x 10 eccentric leg extension on a Cybex Norm dynamometer. Upon arrival, participants will be asked their perceived readiness to perform on a 11 point numeric rating scale. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump. Half way through each set (i.e., after the 5th repetition) participants will be asked to rank their level of difficulty on a 11 point OMNI Res scale. This will occur during each set. Participants will have follow up blood draws, measures of muscle function (i.e, jump height) and soreness measured immediately after and 24 and 48 hours post-exercise.
Study: NCT04905836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient solution
Study: NCT05322083

Intervention type: DRUG
Intervention: Doravirine
Description: Doravirine will be given to patients after failure on the first NNRTI regimen.
Study: NCT06244407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets
Description: Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets
Description: Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
Study: NCT06429696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 inhibitor combined with apatinib
Description: Every 3 weeks (21 days) is a treatment cycle. After 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy until the disease progresses and becomes intolerable. Toxic and side effects, death, withdrawal of information or the investigator's decision to withdraw the subject from the study, non-compliance with study treatment or other reasons specified in the study procedures or protocol, or treatment for up to 2 years. Maintenance treatment: PD-L1 inhibitor + apatinib 250 mg po qd, maintained for up to 2 years. Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w . The selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase.
Study: NCT05972421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Proactive Outreach
Description: phone calls + mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Proactive Outreach
Description: mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
Study: NCT06046183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process group
Description: The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
Study: NCT06655181

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Respiratory Muscle Training
Description: Expiratory muscle training will be performed with POWERbreathe EX1 Medic (POWERbreathe®) device and inspiratory muscle training will be performed with POWERbreathe Medic Classic device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Expiratory muscle training will be performed with POWERbreathe EX1 Medic (POWERbreathe®) device and inspiratory muscle training will be performed with POWERbreathe Medic Classic device.
Study: NCT06499415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU-Calcipotriol
Description: topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU 50 MG/ML Topical Cream
Description: topical 5FU, twice daily, 7 days a week, during 4 weeks
Study: NCT05340569

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted magnetic resonance imaging
Description: See arm description.
Study: NCT06661655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver ultrasound
Description: Hepatoscope is a point of care ultraportable ultrasound device that is capable of conventional grayscale ultrasound imaging, of 2D transient elastography (imaging + liver stiffness measurement), and of quantitative ultrasound properties measurement (ultrasound attenuation, backscattering coefficient, sound speed) related to liver steatosis.
Study: NCT06659796

Intervention type: DEVICE
Intervention: LifeVac
Description: Removal of airway obstruction during choking emergency
Study: NCT06657924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1 gram IV bolus in 100ml of normal saline administered over 10 minutes at the start and end of the surgery for a total of 2 grams TXA
Study: NCT06661135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLPD total laparoscopic pancreaticoduodenectomy
Description: It includes removal of the pancreatic or duodenal tumors using the laparoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OPD open pancreaticoduodenectomy
Description: It includes removal of the pancreatic or duodenal tumors using the open technique
Study: NCT06661811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR-T cells
Study: NCT06661200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMC signal recording
Description: SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMC signal recording
Description: SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMC signal recording
Description: SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.
Study: NCT06658821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LDL557-HK capsule
Description: Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
Study: NCT06662110

Intervention type: DIAGNOSTIC_TEST
Intervention: PSRscore
Description: PSRscore calculated based on baseline serum immune proteomics

Intervention type: DIAGNOSTIC_TEST
Intervention: PSRscore
Description: PSRscore calculated based on baseline serum immune proteomics
Study: NCT06658327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Description: Group A will receive 2\*10 repetitions of dynamic stretching of hamstrings and calf muscles in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Group B will receive 2\*10 repetitions of static stretching of hamstrings and quads in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes. The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
Study: NCT06660680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Received MBI treatment to their surgical incisions upon completion of surgery
Study: NCT06658730

Intervention type: DEVICE
Intervention: Endovascular
Description: TEVAR - thoracic endovascular aortic repair

Intervention type: DEVICE
Intervention: Endovascular
Description: TEVAR - thoracic endovascular aortic repair
Study: NCT06659133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The women participating in the study were divided into control and experimental groups.~The control group included women who underwent pipelle endometrial biopsy with routine care, and the experimental group included women who underwent pipelle endometrial biopsy accompanied by music. Pipelle endometrial biopsy was performed by the same physician working in the Department of Obstetrics and Gynecology at the hospital. Patients in both groups were interviewed 10 minutes before the endometrial biopsy procedure and the Personal Information Form and State and Trait Anxiety Scale were applied. The application of the GKO was explained to the patients before the pipelle endometrial biopsy procedure. Before the pipelle endometrial biopsy, all patients were routinely given local anesthesia with 8 cc of 2% lidocaine solution and waited for 5 minutes after the application of local anesthesia.~During the pipelle endometrial biopsy, the experimental group was given a music recital from an mp3 play
Study: NCT06659653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRG2302
Description: Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
Study: NCT06661512

Intervention type: OTHER
Intervention: Neurorehabilitation program
Description: Participants will participate in a neurorehabilitation program, consisting in a structured, interdisciplinary approach designed to help individuals improve their functional abilities following acquired brain injury. The goal is to optimize the individual's physical, cognitive, emotional, and social functioning to enhance their quality of life~The neurorehabilitation program includes, physical rehabilitation, occupational therapy, speech therapy and neuropsychological rehabilitation (cognitive, emotional and behavioral).
Study: NCT06660511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin in Combination With Anlotinib Hydrochloride
Description: The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)
Study: NCT06614101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exhaled air analysis
Description: The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
Study: NCT04926636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and Wellness Coaching
Description: An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
Study: NCT05273255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
Study: NCT05820139

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control Group
Description: Patients will be randomized to a 200mL (control group)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Test Group
Description: Patients will be randomized to a cut-off of 150mL (test group)
Study: NCT06440954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal pemetrexed
Description: Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
Study: NCT04837118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive handouts containing dietary recommendations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participate in a resistance training program
Study: NCT05223959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted Psychoeducation
Description: This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).